Clearmind Medicine Past Earnings Performance

Past criteria checks 0/6

Clearmind Medicine's earnings have been declining at an average annual rate of -66.1%, while the Pharmaceuticals industry saw earnings growing at 26.2% annually.

Key information

-66.1%

Earnings growth rate

-45.8%

EPS growth rate

Pharmaceuticals Industry Growth23.1%
Revenue growth raten/a
Return on equity-876.6%
Net Marginn/a
Last Earnings Update31 Oct 2023

Recent past performance updates

No updates

Recent updates

We're Not Very Worried About Clearmind Medicine's (CSE:CMND) Cash Burn Rate

Nov 10
We're Not Very Worried About Clearmind Medicine's (CSE:CMND) Cash Burn Rate

Revenue & Expenses Breakdown

How Clearmind Medicine makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

CNSX:CMND Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Oct 230-952
31 Jul 230-633
30 Apr 230-733
31 Jan 230-733
31 Oct 220-733
31 Jul 220-752
30 Apr 220-742
31 Jan 220-441
31 Oct 210-321
31 Jul 210-110
30 Apr 210000
31 Jan 210000
31 Oct 200000
31 Jul 200000
30 Apr 200000
31 Jan 200000
31 Oct 190000
31 Jul 190000
30 Apr 190000
31 Jan 190000
31 Oct 180000

Quality Earnings: CMND is currently unprofitable.

Growing Profit Margin: CMND is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CMND is unprofitable, and losses have increased over the past 5 years at a rate of 66.1% per year.

Accelerating Growth: Unable to compare CMND's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CMND is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (100.1%).


Return on Equity

High ROE: CMND has a negative Return on Equity (-876.57%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies